Company profile: Palatin Technologies
1.1 - Company Overview
Company description
- Provider of targeted receptor-specific peptide therapeutics, including Vyleesi (bremelanotide injection) for premenopausal women with HSDD, and a pipeline of melanocortin-based candidates: PL9643 (Phase 3) for dry eye disease; PL9654 for ocular diseases (IVT and topical); PL8177 (oral, Phase 2) for ulcerative colitis; bremelanotide + PDE5i (Phase 2) for sexual dysfunction; and a planned MCR4 agonist program for obesity.
Products and services
- Vyleesi (bremelanotide injection): Injectable—A treatment for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) delivered as a bremelanotide injection
- PL9643: Ophthalmic—An ophthalmic solution in late-stage Phase 3 clinical development for treating dry eye disease (DED)
- PL8177: Oral—An oral MCR1 agonist in Phase 2 clinical trials for treating ulcerative colitis by resolving inflammation in the colon
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Palatin Technologies
Arch Biopartners
HQ: Canada
Website
- Description: Provider of product acquisition and development for sale to pharmaceutical and industrial companies, with a focus on LSALT peptide (Metablok), a drug candidate that inhibits DPEP1 to target acute organ inflammation in the lungs, liver, and kidneys, including a Phase II international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide for cardiac surgery–associated acute kidney injury.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arch Biopartners company profile →
Medarex
HQ: United States
Website
- Description: Provider of fully human antibody-based therapeutics, focused on discovering, developing and commercializing treatments for life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases, leveraging its UltiMAb technology.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medarex company profile →
Ardea Biosciences
HQ: United States
Website
- Description: Provider of biotechnology development, headquartered in San Diego, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ardea Biosciences company profile →
4P Therapeutics
HQ: United States
Website
- Description: Provider of research and development of novel drug delivery technologies and therapeutics, developing pharmaceutical products from pre-clinical testing to clinical manufacturing, with a focus on meeting the needs of patients, physicians and payers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 4P Therapeutics company profile →
AbbVie
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbbVie company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Palatin Technologies
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Palatin Technologies
2.2 - Growth funds investing in similar companies to Palatin Technologies
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Palatin Technologies
4.2 - Public trading comparable groups for Palatin Technologies
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →